

Technical Appendix

Part D Formulary Prices were used for the primary analysis presented in this study. These input prices are taken directly from the Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files available through the Centers for Medicare and Medicaid Services and represent the plan level average monthly costs for formulary Part D drugs for a 30 day supply of the dose of each drug selected (doses noted in Appendix Table 1 – Formulary Strength). These prices represent the amount reimbursed for the medication and are used as the input for the out-of-pocket price calculation for each Part D formulary.

We further provide measures of drug prices from three additional sources in Appendix Table 1. The first of these is the Memorial Sloan Kettering Cancer Center (MSKCC) monthly drug costs which were obtained via published data available in Howard, David H., Peter B. Bach, Ernst R. Berndt, and Rena M. Conti. 2015. "Pricing in the Market for Anticancer Drugs." *Journal of Economic Perspectives*, 29(1): 139-62 (<https://www.aeaweb.org/articles.php?doi=10.1257/jep.29.1.139>). For the products we examined that were not included in this published source, we utilized the MSKCC website for current prices for 2014 (<https://www.mskcc.org/sites/default/files/node/25097/documents/chemo-prices-table-bach-center-for-health-policy-and-outcomes-7.2.15.pdf>). We also used two current internet-based data sources to evaluate the quality of the input drug pricing data from the CMS Formulary files. The first was "goodrx.com" which is a prescription drug website that advertises discounted prices. For each drug we selected the drug price available from CVS pharmacy (prices were similar across other locations; we chose CVS for consistency). We also used the 2015 Medicare Part D Plan Finder and the methodology proposed by Bach et al, summarized in this document: <https://www.mskcc.org/sites/default/files/node/25097/documents/methods-for-mskcc-website-version-7.2.15.pdf> and in: Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. *N Engl J Med*. 2009 Feb 5;360(6):626-33 to determine prices for a month of therapy among Medicare beneficiaries searching for a Part D plan in 2015. Prices were consistent across the Part D Formulary Price (those used in the primary analysis) and the two external sources for 2015 (goodrx.com and the Medicare Part D Plan Finder). Prices were typically lower when using the prices listed using the MSKCC data. Given this, as a sensitivity analysis we included estimates of the primary comparison between 2010 and 2020 out of pocket payments by beneficiaries using the lowest set of input prices (those from MSKCC) to ensure that our conclusions would not change using a different source of pricing data (see Appendix Table 2).

In order to provide more accurate assessments of potential costs to patients we also borrow from the methodology and data published by Howard et al when defining duration of therapy for included products, using the median duration of therapy based on drug's product labels, published randomized trial results, and cost-effectiveness studies (https://www.aeaweb.org/jep/app/2901/29010139_app.pdf). For products not included in Howard et al's data, we used the drug's product label to identify median duration of therapy. We rounded duration of therapy to the next full month when a partial month was indicated and capped use of a product at 12 months given the benefit design reset in each calendar year.

Appendix Table 1. Median Duration of Drug Use and Estimated Input Price by Data Source

Drug	Median Duration of Use (months)	Part D Formulary Price	Monthly Price MSKCC 2014 / 2015*	GoodRx.com CVS Price - 2015	Part D Plan Finder Humana Enhanced Rx - 2015	Dose for Price (Medscape)	Formulary Strength
Abiraterone	8	\$7,009	\$5,433	\$8,165	\$8,013	1000 mg/day	250mg
Afatinib	11	\$6,279	\$5,500	\$6,611	\$6,487	40 mg/day	20mg
Axitinib	7	\$10,057	\$9,403	\$12,081	\$11,387	10 mg/day	5mg
Cabozantinib	7	\$10,888	\$10,041	\$13,022	\$10,877	140 mg/day	60mg
Crizotinib	8	\$11,908	\$11,375	\$13,743	\$13,494	500mg /day	200mg
Dabrafenib	5	\$8,359	\$9,411	\$9,685	\$8,817	300mg /day	75mg
Dasatinib	12	\$9,516	\$5,220	\$10,572	\$10,379	140mg / day	140mg
Enzalutamide	9	\$8,128	\$7,163	\$9,033	\$8,867	40mg /qday	40mg
Erlotinib	11	\$6,353	\$5,134	\$6,852	\$6,723	150mg / day	150mg
Everolimus	5	\$9,976	\$8,541	\$11,524	\$11,314	10mg / day	5mg
Imatinib	12	\$7,832	\$4,462	\$10,330	\$10,144	400mg/day	400mg
Lapatinib	9	\$5,123	\$3,501	\$5,683	\$5,576	1250mg/day	250mg
Lenalidomide	4	\$13,683	\$9,684	\$13,813	\$14,531	10mg / day	25mg
Nilotinib	12	\$9,543	\$6,881	\$9,872	\$10,383	150mg / day	150mg
Pazopanib	8	\$7,924	\$6,512	\$8,958	\$8,793	800mg / day	200mg
Pomalidomide	8	\$16,093	\$11,336	\$11,999	\$16,829	4mg / days	0.5mg
Regorafenib	3	\$15,206	\$9,736	\$12,756	\$17,890	160mg/day	40mg
Sorafenib	6	\$10,811	\$6,064	\$13,456	\$13,211	800mg/day	200mg
Sunitinib	12	\$13,003	\$5,290	\$13,741	\$14,455	50/mg day	50mg
Trametinib	5	\$9,564	\$8,812	\$10,281	\$10,092	2mg/day	0.5mg
Vandetanib	12	\$11,421	\$10,757	\$13,684	\$12,898	300mg/day	300mg
Vemurafenib	5	\$11,241	\$11,122	\$11,535	\$10,874	1920mg/day	240mg
Vorinostat	4	\$11,469	\$9,552	\$12,437	\$11,747	400mg/day	100mg

Footnote: Median duration of use was obtained from data provided in: Howard, David H., Peter B. Bach, Ernst R. Berndt, and Rena M. Conti. 2015. "Pricing in the Market for Anticancer Drugs." *Journal of Economic Perspectives*, 29(1): 139-62. For products not included in Howard et al., we used the drug's product label to identify median duration of therapy. Monthly prices (based on the Part D Formulary Price) are those reported in the beneficiary cost file within the CMS Formulary data for the formulary strength noted. These prices represent the average amount paid for the specified dose/supply of therapy at in-area retail pharmacies within the plan's service area. Additional price data from other sources are presented, including the MSKCC Monthly price in 2014/2015 (based on Bach et al methodology and published drug prices for 2015), current prices listed on "GoodRx.com" as of August 2015, and prices listed using the Part D Plan Finder Humana Enhanced Rx website (following the Bach et al methodology for plan options available in August 2015).

Appendix Table 2. Median Total Out-of-Pocket Costs for Part D Beneficiaries by Drug before (2010) and after (2020) the Doughnut Hole Closes Assuming a Treatment Course of Median Duration Using Monthly Prices from the MSKCC Drug Price List

Drug	Medicare Advantage Plans (MA-PD)						Stand-Alone PDP					
	2010			2020			2010			2020		
	2010	IQR		2020	IQR		Median (\$)	IQR		Median (\$)	IQR	
Abiraterone	\$6,539	\$6,527	\$6,539	\$3,995	\$3,992	\$3,995	\$6,539	\$6,539	\$6,539	\$3,995	\$3,992	\$3,995
Afatinib	\$7,391	\$7,379	\$7,391	\$4,847	\$4,844	\$4,847	\$7,391	\$7,391	\$7,391	\$4,844	\$4,844	\$4,847
Axitinib	\$7,657	\$7,645	\$7,657	\$5,113	\$5,110	\$5,113	\$7,657	\$7,657	\$7,657	\$5,110	\$5,110	\$5,113
Cabozantinib	\$7,880	\$7,868	\$7,880	\$5,336	\$5,333	\$5,336	\$7,880	\$7,880	\$7,880	\$5,333	\$5,333	\$5,336
Crizotinib	\$8,916	\$8,904	\$8,916	\$6,372	\$6,369	\$6,372	\$8,916	\$8,916	\$8,916	\$6,369	\$6,369	\$6,372
Dabrafenib	\$6,718	\$6,707	\$6,719	\$4,174	\$4,171	\$4,174	\$6,718	\$6,718	\$6,719	\$4,171	\$4,171	\$4,174
Dasatinib	\$7,498	\$6,244	\$7,498	\$4,954	\$4,951	\$4,954	\$7,498	\$7,498	\$7,498	\$4,954	\$4,951	\$4,954
Enzalutamide	\$7,589	\$7,577	\$7,589	\$5,045	\$5,042	\$5,045	\$7,589	\$7,589	\$7,589	\$5,045	\$5,042	\$5,045
Erlotinib	\$7,189	\$7,178	\$7,190	\$4,645	\$4,642	\$4,645	\$7,189	\$7,189	\$7,190	\$4,642	\$4,642	\$4,645
Everolimus	\$6,501	\$4,007	\$6,501	\$3,957	\$3,954	\$3,957	\$6,501	\$6,501	\$6,501	\$3,957	\$3,954	\$3,957
Imatinib	\$7,043	\$7,031	\$7,043	\$4,499	\$4,496	\$4,499	\$7,043	\$7,043	\$7,043	\$4,496	\$4,496	\$4,499
Lapatinib	\$5,941	\$5,929	\$5,941	\$3,397	\$3,394	\$3,397	\$5,941	\$5,941	\$5,941	\$3,394	\$3,394	\$3,397
Lenalidomide	\$6,302	\$3,808	\$6,303	\$3,758	\$3,755	\$3,758	\$6,302	\$6,302	\$6,303	\$3,758	\$3,755	\$3,758
Nilotinib	\$8,494	\$8,483	\$8,494	\$5,950	\$5,947	\$5,950	\$8,494	\$8,494	\$8,494	\$5,947	\$5,947	\$5,950
Pazopanib	\$6,971	\$6,959	\$6,971	\$4,426	\$4,423	\$4,426	\$6,970	\$6,970	\$6,971	\$4,426	\$4,423	\$4,426
Pomalidomide	\$8,900	\$8,887	\$8,900	\$6,356	\$6,353	\$6,356	\$8,900	\$8,900	\$8,900	\$6,356	\$6,353	\$6,356
Regorafenib	\$5,826	\$5,814	\$5,826	\$3,282	\$3,279	\$3,282	\$5,826	\$5,826	\$5,826	\$3,282	\$3,279	\$3,282
Sorafenib	\$6,185	\$6,173	\$6,185	\$3,641	\$3,638	\$3,641	\$6,185	\$6,185	\$6,185	\$3,641	\$3,638	\$3,641
Sunitinib	\$7,540	\$7,528	\$7,540	\$4,996	\$4,993	\$4,996	\$7,540	\$7,540	\$7,540	\$4,993	\$4,993	\$4,996
Trametinib	\$6,569	\$6,557	\$6,569	\$4,025	\$4,022	\$4,025	\$6,569	\$6,569	\$6,569	\$4,022	\$4,022	\$4,025
Vandetanib	\$10,820	\$10,808	\$10,820	\$8,276	\$8,273	\$8,276	\$10,820	\$10,820	\$10,820	\$8,273	\$8,273	\$8,276
Vemurafenib	\$7,146	\$7,135	\$7,146	\$4,602	\$4,599	\$4,602	\$7,146	\$7,146	\$7,146	\$4,602	\$4,599	\$4,602
Vorinostat	\$6,276	\$6,264	\$6,276	\$3,732	\$3,729	\$3,732	\$6,276	\$6,276	\$6,276	\$3,732	\$3,729	\$3,732

Footnote: Memorial Sloan Kettering Cancer Center (MSKCC) monthly drug costs which were obtained via published data available in Howard, David H., Peter B. Bach, Ernst R. Berndt, and Rena M. Conti. 2015. "Pricing in the Market for Anticancer Drugs." *Journal of Economic Perspectives*, 29(1): 139-62 (<https://www.aeaweb.org/articles.php?doi=10.1257/jep.29.1.139>). For the products included here that were not included in this published source we utilized the MSKCC website for current prices for 2014 <https://www.mskcc.org/sites/default/files/node/25097/documents/chemo-prices-table-bach-center-for-health-policy-and-outcomes-7.2.15.pdf>.

Appendix Table 3. Median Total Out-of-Pocket Costs for Part D Beneficiaries by Drug before (2010) and after (2020) the Doughnut Hole Closes Assuming a Treatment Course of Median Duration

Drug	Medicare Advantage Plans (MA-PD)						Stand-Alone PDP					
	2010			2020			2010			2020		
	2010	IQR		2020	IQR		Median (\$)	IQR		Median (\$)	IQR	
Abiraterone	\$7,156	\$7,098	\$7,200	\$4,621	\$4,586	\$4,655	\$7,163	\$7,146	\$7,199	\$4,619	\$4,603	\$4,654
Afatinib	\$7,817	\$7,721	\$7,839	\$5,242	\$5,229	\$5,293	\$7,819	\$7,781	\$7,864	\$5,275	\$5,234	\$5,297
Axitinib	\$7,877	\$7,777	\$7,935	\$5,345	\$5,285	\$5,383	\$7,855	\$7,828	\$7,919	\$5,314	\$5,286	\$5,379
Cabozantinib	\$8,174	\$8,073	\$8,201	\$5,597	\$5,586	\$5,654	\$8,176	\$8,135	\$8,225	\$5,632	\$5,588	\$5,657
Crizotinib	\$9,120	\$8,955	\$9,174	\$6,552	\$6,529	\$6,626	\$9,122	\$9,024	\$9,168	\$6,594	\$6,487	\$6,621
Dabrafenib	\$6,454	\$6,373	\$6,468	\$3,889	\$3,875	\$3,922	\$6,456	\$6,433	\$6,482	\$3,912	\$3,886	\$3,925
Dasatinib	\$10,075	\$8,843	\$10,146	\$7,531	\$7,508	\$7,602	\$10,074	\$9,983	\$10,145	\$7,528	\$7,438	\$7,601
Enzalutamide	\$8,002	\$7,940	\$8,081	\$5,480	\$5,434	\$5,509	\$7,999	\$7,977	\$8,046	\$5,456	\$5,435	\$5,499
Erlotinib	\$7,853	\$7,795	\$7,888	\$5,309	\$5,271	\$5,338	\$7,857	\$7,835	\$7,900	\$5,312	\$5,292	\$5,346
Everolimus	\$6,836	\$4,340	\$6,865	\$4,291	\$4,277	\$4,321	\$6,862	\$6,835	\$6,895	\$4,318	\$4,287	\$4,344
Imatinib	\$9,062	\$8,989	\$9,097	\$6,508	\$6,458	\$6,548	\$9,063	\$9,022	\$9,107	\$6,519	\$6,478	\$6,562
Lapatinib	\$6,660	\$6,622	\$6,699	\$4,121	\$4,096	\$4,145	\$6,656	\$6,643	\$6,686	\$4,112	\$4,099	\$4,142
Lenalidomide	\$7,084	\$4,758	\$7,132	\$4,561	\$4,528	\$4,575	\$7,082	\$7,065	\$7,116	\$4,536	\$4,522	\$4,570
Nilotinib	\$10,083	\$9,959	\$10,159	\$7,545	\$7,486	\$7,614	\$10,082	\$10,041	\$10,153	\$7,536	\$7,501	\$7,604
Pazopanib	\$7,518	\$7,460	\$7,572	\$4,981	\$4,942	\$5,016	\$7,518	\$7,495	\$7,559	\$4,974	\$4,954	\$5,014
Pomalidomide	\$10,800	\$10,563	\$10,841	\$8,223	\$8,188	\$8,293	\$10,805	\$10,734	\$10,872	\$8,261	\$8,188	\$8,320
Regorafenib	\$6,630	\$6,593	\$6,679	\$4,099	\$4,067	\$4,131	\$6,625	\$6,613	\$6,658	\$4,081	\$4,069	\$4,113
Sorafenib	\$7,598	\$7,563	\$7,653	\$5,063	\$5,031	\$5,098	\$7,596	\$7,575	\$7,638	\$5,052	\$5,033	\$5,093
Sunitinib	\$12,163	\$11,963	\$12,263	\$9,623	\$9,544	\$9,723	\$12,160	\$12,102	\$12,262	\$9,617	\$9,565	\$9,716
Trametinib	\$6,756	\$6,663	\$6,772	\$4,188	\$4,174	\$4,227	\$6,758	\$6,732	\$6,789	\$4,214	\$4,185	\$4,230
Vandetanib	\$11,218	\$11,031	\$11,262	\$8,650	\$8,601	\$8,717	\$11,220	\$11,147	\$11,267	\$8,672	\$8,600	\$8,723
Vemurafenib	\$7,149	\$7,101	\$7,210	\$4,623	\$4,581	\$4,657	\$7,158	\$7,129	\$7,198	\$4,613	\$4,586	\$4,657
Vorinostat	\$6,650	\$6,604	\$6,688	\$4,112	\$4,074	\$4,141	\$6,643	\$6,619	\$6,682	\$4,099	\$4,075	\$4,138

Footnote: Authors analysis of the July 15, 2014 quarterly release of the Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files from the Center for Medicaid and Medicare Services. Input price is from the formulary files and represents the average reimbursed amount across each plan for the product listed for one month of therapy at the mean recommended dose. Median duration of use was obtained from data provided in: Howard, David H., Peter B. Bach, Ernst R. Berndt, and Rena M. Conti. 2015. "Pricing in the Market for Anticancer Drugs." *Journal of Economic Perspectives*, 29(1): 139-62. For products not included in Howard et al., we used the drug's product label to identify median duration of therapy (See Technical Appendix for further details).

Appendix Table 4. Median Total Out-of-Pocket Costs for Part D Beneficiaries by Drug before (2010) and after (2020) the Doughnut Hole Closes for 3 Months of Product Use

Drug	Medicare Advantage Plans (MA-PD)						Stand-Alone PDP					
	2010			2020			2010			2020		
	2010	IQR		2020	IQR		Median (\$)	IQR		Median (\$)	IQR	
Abiraterone	\$5,412	\$5,388	\$5,428	\$2,870	\$2,856	\$2,884	\$5,415	\$5,408	\$5,428	\$2,869	\$2,862	\$2,883
Afatinib	\$5,307	\$5,276	\$5,313	\$2,753	\$2,745	\$2,768	\$5,308	\$5,297	\$5,318	\$2,763	\$2,750	\$2,770
Axitinib	\$5,868	\$5,828	\$5,896	\$3,330	\$3,301	\$3,348	\$5,861	\$5,850	\$5,889	\$3,316	\$3,305	\$3,345
Cabozantinib	\$5,998	\$5,952	\$6,009	\$3,439	\$3,429	\$3,464	\$5,999	\$5,981	\$6,019	\$3,455	\$3,434	\$3,465
Crizotinib	\$6,146	\$6,087	\$6,168	\$3,596	\$3,572	\$3,622	\$6,150	\$6,113	\$6,166	\$3,610	\$3,568	\$3,619
Dabrafenib	\$5,618	\$5,569	\$5,627	\$3,062	\$3,048	\$3,082	\$5,620	\$5,606	\$5,635	\$3,076	\$3,059	\$3,084
Dasatinib	\$5,793	\$4,550	\$5,811	\$3,249	\$3,231	\$3,267	\$5,792	\$5,770	\$5,811	\$3,246	\$3,224	\$3,266
Enzalutamide	\$5,578	\$5,556	\$5,603	\$3,036	\$3,023	\$3,051	\$5,577	\$5,569	\$5,592	\$3,031	\$3,024	\$3,046
Erlotinib	\$5,316	\$5,299	\$5,326	\$2,771	\$2,758	\$2,779	\$5,318	\$5,312	\$5,330	\$2,771	\$2,766	\$2,781
Everolimus	\$5,847	\$3,353	\$5,867	\$3,303	\$3,289	\$3,321	\$5,864	\$5,847	\$5,884	\$3,319	\$3,300	\$3,331
Imatinib	\$5,538	\$5,520	\$5,548	\$2,991	\$2,976	\$3,001	\$5,540	\$5,530	\$5,551	\$2,994	\$2,984	\$3,004
Lapatinib	\$5,130	\$5,116	\$5,142	\$2,587	\$2,576	\$2,596	\$5,129	\$5,125	\$5,139	\$2,584	\$2,579	\$2,594
Lenalidomide	\$6,404	\$4,036	\$6,439	\$3,875	\$3,850	\$3,887	\$6,403	\$6,390	\$6,428	\$3,857	\$3,847	\$3,883
Nilotinib	\$5,794	\$5,764	\$5,814	\$3,251	\$3,227	\$3,270	\$5,795	\$5,784	\$5,813	\$3,248	\$3,239	\$3,266
Pazopanib	\$5,548	\$5,523	\$5,566	\$3,005	\$2,987	\$3,019	\$5,548	\$5,539	\$5,563	\$3,002	\$2,994	\$3,018
Pomalidomide	\$6,778	\$6,690	\$6,794	\$4,210	\$4,201	\$4,249	\$6,780	\$6,754	\$6,812	\$4,236	\$4,207	\$4,252
Regorafenib	\$6,630	\$6,593	\$6,679	\$4,099	\$4,067	\$4,131	\$6,625	\$6,613	\$6,658	\$4,081	\$4,069	\$4,113
Sorafenib	\$5,982	\$5,962	\$6,009	\$3,440	\$3,422	\$3,459	\$5,981	\$5,971	\$6,002	\$3,436	\$3,426	\$3,457
Sunitinib	\$6,313	\$6,265	\$6,340	\$3,771	\$3,741	\$3,797	\$6,314	\$6,300	\$6,340	\$3,768	\$3,756	\$3,793
Trametinib	\$5,800	\$5,743	\$5,810	\$3,242	\$3,228	\$3,264	\$5,801	\$5,785	\$5,819	\$3,257	\$3,238	\$3,266
Vandetanib	\$6,078	\$6,028	\$6,090	\$3,520	\$3,510	\$3,546	\$6,078	\$6,061	\$6,091	\$3,532	\$3,513	\$3,543
Vemurafenib	\$6,036	\$6,007	\$6,072	\$3,501	\$3,474	\$3,523	\$6,041	\$6,024	\$6,066	\$3,495	\$3,479	\$3,522
Vorinostat	\$6,079	\$6,044	\$6,107	\$3,539	\$3,510	\$3,560	\$6,074	\$6,056	\$6,103	\$3,529	\$3,511	\$3,558

Footnote: Authors analysis of the July 15, 2014 quarterly release of the Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files from the Center for Medicaid and Medicare Services. Input price is from the formulary files and represents the average reimbursed amount across each plan for the product listed for one month of therapy at the mean recommended dose. Duration of therapy set at 3 months to estimate out-of-pocket prices for each product using the minimum duration of therapy across all products.

Appendix Table 5. Median Total Out-of-Pocket Costs for Part D Beneficiaries by Drug before (2010) and after (2020) the Doughnut Hole Closes for 12 Months of Product Use

Drug	Medicare Advantage Plans (MA-PD)						Stand-Alone PDP					
	2010			2020			2010			2020		
	2010	IQR		2020	IQR		Median (\$)	IQR		Median (\$)	IQR	
Abiraterone	\$8,552	\$8,467	\$8,616	\$6,023	\$5,976	\$6,072	\$8,562	\$8,536	\$8,616	\$6,020	\$5,995	\$6,071
Afatinib	\$8,131	\$8,026	\$8,155	\$5,553	\$5,543	\$5,608	\$8,133	\$8,092	\$8,181	\$5,589	\$5,545	\$5,613
Axitinib	\$10,387	\$10,213	\$10,485	\$7,866	\$7,774	\$7,928	\$10,346	\$10,301	\$10,454	\$7,818	\$7,761	\$7,920
Cabozantinib	\$10,895	\$10,722	\$10,940	\$8,329	\$8,280	\$8,391	\$10,898	\$10,827	\$10,966	\$8,354	\$8,280	\$8,410
Crizotinib	\$11,499	\$11,250	\$11,578	\$8,917	\$8,891	\$9,032	\$11,495	\$11,353	\$11,569	\$8,981	\$8,822	\$9,022
Dabrafenib	\$9,377	\$9,194	\$9,411	\$6,794	\$6,774	\$6,863	\$9,382	\$9,327	\$9,438	\$6,837	\$6,780	\$6,872
Dasatinib	\$10,075	\$8,843	\$10,146	\$7,531	\$7,508	\$7,602	\$10,074	\$9,983	\$10,145	\$7,528	\$7,438	\$7,601
Enzalutamide	\$9,215	\$9,133	\$9,321	\$6,709	\$6,643	\$6,746	\$9,210	\$9,180	\$9,272	\$6,669	\$6,639	\$6,726
Erlotinib	\$8,171	\$8,107	\$8,209	\$5,626	\$5,585	\$5,660	\$8,174	\$8,150	\$8,221	\$5,630	\$5,608	\$5,668
Everolimus	\$10,295	\$7,797	\$10,365	\$7,748	\$7,739	\$7,821	\$10,357	\$10,291	\$10,426	\$7,812	\$7,744	\$7,886
Imatinib	\$9,062	\$8,989	\$9,097	\$6,508	\$6,458	\$6,548	\$9,063	\$9,022	\$9,107	\$6,519	\$6,478	\$6,562
Lapatinib	\$7,424	\$7,374	\$7,478	\$4,892	\$4,857	\$4,919	\$7,419	\$7,402	\$7,460	\$4,876	\$4,858	\$4,915
Lenalidomide	\$12,519	\$10,382	\$12,666	\$10,060	\$9,963	\$10,098	\$12,514	\$12,465	\$12,616	\$9,972	\$9,925	\$10,071
Nilotinib	\$10,083	\$9,959	\$10,159	\$7,545	\$7,486	\$7,614	\$10,082	\$10,041	\$10,153	\$7,536	\$7,501	\$7,604
Pazopanib	\$9,095	\$9,010	\$9,176	\$6,566	\$6,510	\$6,618	\$9,095	\$9,060	\$9,156	\$6,550	\$6,521	\$6,611
Pomalidomide	\$14,018	\$13,662	\$14,079	\$11,451	\$11,375	\$11,535	\$14,024	\$13,919	\$14,113	\$11,480	\$11,372	\$11,584
Regorafenib	\$13,425	\$13,275	\$13,618	\$10,970	\$10,831	\$11,071	\$13,404	\$13,354	\$13,531	\$10,868	\$10,811	\$10,991
Sorafenib	\$10,831	\$10,763	\$10,941	\$8,320	\$8,246	\$8,387	\$10,826	\$10,785	\$10,909	\$8,284	\$8,245	\$8,365
Sunitinib	\$12,163	\$11,963	\$12,263	\$9,623	\$9,544	\$9,723	\$12,160	\$12,102	\$12,262	\$9,617	\$9,565	\$9,716
Trametinib	\$10,102	\$9,895	\$10,141	\$7,528	\$7,495	\$7,593	\$10,107	\$10,045	\$10,169	\$7,563	\$7,498	\$7,608
Vandetanib	\$11,218	\$11,031	\$11,262	\$8,650	\$8,601	\$8,717	\$11,220	\$11,147	\$11,267	\$8,672	\$8,600	\$8,723
Vemurafenib	\$11,050	\$10,929	\$11,194	\$8,564	\$8,462	\$8,635	\$11,065	\$10,998	\$11,154	\$8,526	\$8,457	\$8,628
Vorinostat	\$11,224	\$11,076	\$11,332	\$8,703	\$8,612	\$8,788	\$11,196	\$11,126	\$11,315	\$8,663	\$8,588	\$8,770

Footnote: Authors analysis of the July 15, 2014 quarterly release of the Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files from the Center for Medicaid and Medicare Services. Input price is from the formulary files and represents the average reimbursed amount across each plan for the product listed for one month of therapy at the mean recommended dose. Duration of therapy set at 12 months to estimate out-of-pocket prices for each product using the maximum duration of therapy for a single year across all products.